ATE362473T1 - 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten - Google Patents

1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten

Info

Publication number: ATE362473T1
Authority: AT; Austria
Prior art keywords: döpyrimidine; csbp; disubstituted; dihydro; kinase
Prior art date: 2000-03-02

Application number

AT01914625T

Other languages

German (de)

English (en)

Inventor

Jerry Adams

Jeffrey Boehm

Ralph Hall

John Taggart

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-02

Filing date

2001-03-02

Publication date

2007-06-15

2001-03-02 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE362473T1 publication Critical patent/ATE362473T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Immunology (AREA)
Neurology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)

AT01914625T 2000-03-02 2001-03-02 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten ATE362473T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18641900P	2000-03-02	2000-03-02

Publications (1)

Publication Number	Publication Date
ATE362473T1 true ATE362473T1 (de)	2007-06-15

Family

ID=22684876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01914625T ATE362473T1 (de)	2000-03-02	2001-03-02	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten

Country Status (25)

Country	Link
EP (1)	EP1265900B1 (fr)
JP (1)	JP2003525295A (fr)
KR (1)	KR100806978B1 (fr)
CN (1)	CN100482664C (fr)
AR (2)	AR030053A1 (fr)
AT (1)	ATE362473T1 (fr)
AU (2)	AU2001239992B2 (fr)
BR (1)	BR0108715A (fr)
CA (1)	CA2402092C (fr)
CY (1)	CY1106816T1 (fr)
CZ (1)	CZ20022933A3 (fr)
DE (1)	DE60128457T2 (fr)
DK (1)	DK1265900T3 (fr)
ES (1)	ES2287107T3 (fr)
HU (1)	HUP0204431A3 (fr)
IL (3)	IL151426A0 (fr)
MX (1)	MXPA02008588A (fr)
MY (1)	MY141144A (fr)
NO (1)	NO326409B1 (fr)
NZ (1)	NZ520914A (fr)
PL (1)	PL358280A1 (fr)
PT (1)	PT1265900E (fr)
TW (1)	TWI290926B (fr)
WO (1)	WO2001064679A1 (fr)
ZA (1)	ZA200207017B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
EE200000706A (et)	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
AU1782301A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
AU1781601A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
DE60020595T2 (de)	1999-11-23	2006-03-16	Smithkline Beecham Corp.	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
KR100850812B1 (ko) *	2000-10-23	2008-08-06	스미스클라인 비참 코포레이션	신규 화합물
EP1345603A4 (fr) *	2000-12-20	2004-09-08	Merck & Co Inc	Agents inhibiteurs de p38 kinase (halo-benzo carbonyl)heterocyclo- fusionnes phenyl
GB0124848D0 (en)	2001-10-16	2001-12-05	Celltech R&D Ltd	Chemical compounds
ES2295553T3 (es)	2002-02-12	2008-04-16	Smithkline Beecham Corporation	Derivados de nicotinamida utiles como inhibidores de p38.
CN1324015C (zh) *	2002-02-13	2007-07-04	霍夫曼-拉罗奇有限公司	吡啶－和嘧啶－衍生物
WO2003088972A1 (fr) *	2002-04-19	2003-10-30	Smithkline Beecham Corporation	Nouveaux composes
GB0214268D0 (en) *	2002-06-20	2002-07-31	Celltech R&D Ltd	Chemical compounds
US7196090B2 (en)	2002-07-25	2007-03-27	Warner-Lambert Company	Kinase inhibitors
GB0218800D0 (en) *	2002-08-13	2002-09-18	Celltech R&D Ltd	Chemical compounds
US7084270B2 (en)	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
WO2004019873A2 (fr)	2002-08-29	2004-03-11	Scios Inc.	Methode pour favoriser l'osteogenese
US7129351B2 (en)	2002-11-04	2006-10-31	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
WO2004043367A2 (fr)	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Composes heterocycliques fusionnes et leur utilisation
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR20050111636A (ko)	2003-04-10	2005-11-25	에프. 호프만-라 로슈 아게	피리미도 화합물
US7244441B2 (en)	2003-09-25	2007-07-17	Scios, Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
WO2005063766A2 (fr) *	2003-12-23	2005-07-14	Novartis Ag	Inhibiteurs heterocycliques bicycliques des kinases p-38
JP5111113B2 (ja) *	2004-12-13	2012-12-26	サネシスファーマシューティカルズ，インコーポレイテッド	Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
EP1676574A3 (fr)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Procédé favorisant la survie des tissus ou cellules griffées
JP5201817B2 (ja) *	2005-10-28	2013-06-05	大塚製薬株式会社	医薬組成物
US20100069409A1 (en) *	2006-06-16	2010-03-18	Glaxo Group Limited	"novel compounds"
JP2009542818A (ja) *	2006-06-16	2009-12-03	グラクソグループリミテッド	新規化合物
KR101040394B1 (ko) *	2010-05-18	2011-06-09	(주)이성산업	역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) *	2011-06-10	2016-04-27	中国科学院广州生物医药与健康研究院	嘧啶并嘧啶酮类化合物及其药用组合物和应用
MY181020A (en)	2013-03-15	2020-12-16	Sanofi Sa	Heteroaryl compounds and uses thereof
AR095464A1 (es)	2013-03-15	2015-10-21	Celgene Avilomics Res Inc	Compuestos de heteroarilo y usos de los mismos
SG11201507478VA (en)	2013-03-15	2015-10-29	Celgene Avilomics Res Inc	Heteroaryl compounds and uses thereof
KR101982912B1 (ko) *	2013-10-16	2019-09-10	상하이 잉리 파마슈티컬 컴퍼니 리미티드	융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt)	2017-10-05	2022-10-06	Fulcrum Therapeutics Inc	Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
TW202327600A (zh)	2021-10-20	2023-07-16	香港商英科智能有限公司	甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60226882A (ja) *	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
ATE232863T1 (de) *	1996-08-06	2003-03-15	Pfizer	Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
EE200000706A (et) *	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
JP2002517486A (ja) *	1998-06-12	2002-06-18	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
EP1123295B1 (fr) *	1998-10-23	2004-09-29	F. Hoffmann-La Roche Ag	Heterocycles d'azote bicycliques

2001
- 2001-02-28 AR ARP010100940A patent/AR030053A1/es unknown
- 2001-02-28 MY MYPI20010900A patent/MY141144A/en unknown
- 2001-03-02 JP JP2001564176A patent/JP2003525295A/ja active Pending
- 2001-03-02 EP EP01914625A patent/EP1265900B1/fr not_active Expired - Lifetime
- 2001-03-02 KR KR1020027011408A patent/KR100806978B1/ko not_active Expired - Fee Related
- 2001-03-02 DE DE60128457T patent/DE60128457T2/de not_active Expired - Lifetime
- 2001-03-02 DK DK01914625T patent/DK1265900T3/da active
- 2001-03-02 AU AU2001239992A patent/AU2001239992B2/en not_active Ceased
- 2001-03-02 CN CNB018076866A patent/CN100482664C/zh not_active Expired - Fee Related
- 2001-03-02 CZ CZ20022933A patent/CZ20022933A3/cs unknown
- 2001-03-02 HU HU0204431A patent/HUP0204431A3/hu unknown
- 2001-03-02 NZ NZ520914A patent/NZ520914A/en not_active IP Right Cessation
- 2001-03-02 AT AT01914625T patent/ATE362473T1/de active
- 2001-03-02 WO PCT/US2001/006688 patent/WO2001064679A1/fr not_active Ceased
- 2001-03-02 ES ES01914625T patent/ES2287107T3/es not_active Expired - Lifetime
- 2001-03-02 IL IL15142601A patent/IL151426A0/xx active IP Right Grant
- 2001-03-02 PL PL01358280A patent/PL358280A1/xx not_active Application Discontinuation
- 2001-03-02 TW TW090104783A patent/TWI290926B/zh not_active IP Right Cessation
- 2001-03-02 BR BR0108715-0A patent/BR0108715A/pt not_active Application Discontinuation
- 2001-03-02 CA CA2402092A patent/CA2402092C/fr not_active Expired - Fee Related
- 2001-03-02 AU AU3999201A patent/AU3999201A/xx active Pending
- 2001-03-02 MX MXPA02008588A patent/MXPA02008588A/es active IP Right Grant
- 2001-03-02 PT PT01914625T patent/PT1265900E/pt unknown
2002
- 2002-08-22 IL IL151426A patent/IL151426A/en not_active IP Right Cessation
- 2002-08-30 NO NO20024134A patent/NO326409B1/no not_active IP Right Cessation
- 2002-09-02 ZA ZA200207017A patent/ZA200207017B/en unknown
2003
- 2003-05-07 AR ARP030101602A patent/AR040075A2/es unknown
2007
- 2007-08-13 CY CY20071101080T patent/CY1106816T1/el unknown
2008
- 2008-02-28 IL IL189865A patent/IL189865A0/en unknown

Also Published As

Publication number	Publication date
NO20024134L (no)	2002-10-24
ES2287107T3 (es)	2007-12-16
KR100806978B1 (ko)	2008-02-25
HK1052932A1 (en)	2003-10-03
DE60128457T2 (de)	2008-01-17
DK1265900T3 (da)	2007-09-24
HUP0204431A1 (hu)	2003-04-28
WO2001064679A1 (fr)	2001-09-07
CN100482664C (zh)	2009-04-29
CN1422273A (zh)	2003-06-04
DE60128457D1 (de)	2007-06-28
CA2402092A1 (fr)	2001-09-07
KR20020082858A (ko)	2002-10-31
MY141144A (en)	2010-03-15
NO326409B1 (no)	2008-12-01
CA2402092C (fr)	2012-01-24
EP1265900A4 (fr)	2004-11-10
CZ20022933A3 (cs)	2003-02-12
CY1106816T1 (el)	2012-01-25
JP2003525295A (ja)	2003-08-26
IL151426A0 (en)	2003-04-10
AR040075A2 (es)	2005-03-16
TWI290926B (en)	2007-12-11
EP1265900A1 (fr)	2002-12-18
BR0108715A (pt)	2004-04-27
PT1265900E (fr)	2007-08-22
ZA200207017B (en)	2004-02-26
MXPA02008588A (es)	2003-02-24
IL189865A0 (en)	2008-08-07
AU2001239992B2 (en)	2005-09-01
EP1265900B1 (fr)	2007-05-16
NO20024134D0 (no)	2002-08-30
AU3999201A (en)	2001-09-12
HUP0204431A3 (en)	2006-01-30
PL358280A1 (en)	2004-08-09
NZ520914A (en)	2004-03-26
IL151426A (en)	2011-01-31
AR030053A1 (es)	2003-08-13

Publication	Publication Date	Title
ATE362473T1 (de)	2007-06-15	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
DE60112791D1 (de)	2005-09-22	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
ATE521353T1 (de)	2011-09-15	Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
DE60233265D1 (de)	2009-09-17	5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE602004015269D1 (de)	2008-09-04	Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
ATE446286T1 (de)	2009-11-15	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
ATE327757T1 (de)	2006-06-15	Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
DE69916828D1 (de)	2004-06-03	Pyrazoline, ihre herstellung und verwendung als medikamente
DE60121294D1 (de)	2006-08-17	Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE448238T1 (de)	2009-11-15	3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
ATE232865T1 (de)	2003-03-15	1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
ATE318821T1 (de)	2006-03-15	Pyranoindazole und ihre verwendung in der glaukombehandlung
ATE422202T1 (de)	2009-02-15	Substituierte 4-(indazol-3-yl)phenole als liganden des oestrogenrezeptors und deren verwendung bei der behandlung von entzündlichen erkrankungen
ATE290534T1 (de)	2005-03-15	4-(oxadiazol-3-yl)-1,4-diazabizyklo(3.2.2)- nonanderivate, ihre herstellung und therapeutische verwendung
DE60230883D1 (de)	2009-03-05	Neue formulierungen und ihre verwendung
ATE265454T1 (de)	2004-05-15	Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
DE60130365D1 (de)	2007-10-18	Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
DE50003275D1 (de)	2003-09-18	Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE60221275D1 (de)	2007-08-30	Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE69106199D1 (de)	1995-02-09	Heterocyclische Acetonitrile und ihre Verwendung als Fungizide.
DE50313185D1 (de)	2010-11-25	2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE69132782D1 (de)	2001-11-29	Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
DE60217870D1 (de)	2007-03-15	Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
EE200300535A (et)	2004-02-16	4-(fenüül(piperidiin-4-üül)amino)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks
EE200300554A (et)	2004-02-16	4-(fenüül(piperidiin-4-üül)amino)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse või seedetrakti häirete ravis

Legal Events

Date	Code	Title	Description
2007-11-15	UEP	Publication of translation of european patent specification	Ref document number: 1265900 Country of ref document: EP

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1265900

Country of ref document: EP